Podcast: Download (Duration: 1:00 — 938.4KB) | Embed

Subscribe: Apple Podcasts | Spotify | RSS

ARISTOPHANES Study

An analysis of over 160,000 non-valvular atrial fibrillation patients has found that Eliquis, a direct oralanticoagulant or DOAC, had lower rates of major bleeding and stroke/systemic embolism in a series of head-to-head comparisons among Eliquis, Pradaxa, and Xarelto.

Eliquis has a 17% lower rate of stroke/systemic embolism and a 46% lower rate of major bleeding compared with Xarelto.
Eliquis has a 31% lower rate of stroke/systemic embolism and a 23% lower rate of major bleeding compared with Pradaxa.

There is a significant safety advantage that DOAC’s like Eliquis have over warfarin, especially in regards to intracranial bleeding.

Resource
https://www.ahajournals.org/doi/10.1161/STROKEAHA.118.020232
https://www.eliquis.bmscustomerconnect.com/

Related Episodes

• • Health & Wellness
  • Medical
  • Pharmaceuticals

  Atherosclerosis Cleanup
• • Health & Wellness
  • Medical
  • Medical Devices
  • Specialty - Cardiology

  Bystander Defibrillator Use Improves Cardiac Arrest Survival